<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004013</url>
  </required_header>
  <id_info>
    <org_study_id>1338.00</org_study_id>
    <secondary_id>FHCRC-1338.00</secondary_id>
    <secondary_id>GENENTECH-FHCRC-1338.00</secondary_id>
    <secondary_id>NCI-G99-1557</secondary_id>
    <secondary_id>CDR0000067230</secondary_id>
    <nct_id>NCT00004013</nct_id>
  </id_info>
  <brief_title>Paclitaxel With or Without Trastuzumab Following Peripheral Stem Cell Transplantation in Treating Patients With Refractory Stage IV Breast Cancer</brief_title>
  <official_title>Treatment of Refractory Stage IV Metastatic Breast Cancer With Weekly Paclitaxel or Weekly Paclitaxel and Herceptin Following Autologous/Syngeneic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells&#xD;
      and either kill them or deliver tumor-killing substances to them without harming normal&#xD;
      cells. Paclitaxel may stop the growth of breast cancer by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: Phase II trial to compare the effectiveness of paclitaxel with or without&#xD;
      trastuzumab following peripheral stem cell transplantation in treating patients who have&#xD;
      refractory stage IV breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the toxicity of paclitaxel with or without trastuzumab following&#xD;
      high dose chemotherapy with autologous or syngeneic peripheral blood stem cell&#xD;
      transplantation in patients with stage IV breast cancer. II. Assess the overall survival of&#xD;
      these patients.&#xD;
&#xD;
      OUTLINE: Patients begin study treatment within 50-150 days after autologous or syngeneic&#xD;
      peripheral blood stem cell transplantation. Patients are stratified according to&#xD;
      overexpression of HER2-Neu (yes vs no), which determines the type of therapy. Arm I&#xD;
      (overexpression of HER2-Neu): Patients receive paclitaxel IV over 60 minutes followed by the&#xD;
      initial loading dose of trastuzumab IV over 90 minutes. If the loading dose is tolerated&#xD;
      well, then patients receive maintenance trastuzumab IV over 30 minutes. Treatment with&#xD;
      paclitaxel followed by maintenance trastuzumab repeats once every week for 12 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity. Arm II (no overexpression of&#xD;
      Her2-Neu): Patients receive paclitaxel IV over 60 minutes once every week for 12 weeks.&#xD;
      Patients with hormone receptor positive disease also receive antihormonal therapy (tamoxifen&#xD;
      or anastrozole) as clinically indicated. Patients with isolated metastasis such as a single&#xD;
      bone lesion may receive radiotherapy to that site after completion of study treatment.&#xD;
      Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (30 per arm) will be accrued for this study over&#xD;
      2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">October 2001</completion_date>
  <primary_completion_date type="Actual">October 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Refractory stage IV breast cancer Received high dose chemotherapy&#xD;
        (HDC) with autologous or syngeneic peripheral blood stem cell transplantation (PBSCT) OR&#xD;
        Stage IV breast cancer Failed to achieve complete response to HDC with autologous or&#xD;
        syngeneic PBSCT at initial restaging following HDC No enrollment on protocol FHCRC-976,&#xD;
        unless evidence of no response or progressive disease at initial restaging following&#xD;
        transplantation Hormone receptor status: Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Not specified Menopausal status: Not specified Performance&#xD;
        status: Karnofsky 70-100% Life expectancy: Not specified Hematopoietic: Platelet count at&#xD;
        least 50,000/mm3 (untransfused) Absolute neutrophil count greater than 1,000/mm3 (without&#xD;
        filgrastim (G-CSF) support) Hepatic: Bilirubin no greater than 2.5 times upper limit of&#xD;
        normal (ULN) SGOT no greater than 2.5 times ULN Renal: Creatinine no greater than 2.0 mg/dL&#xD;
        Cardiovascular: LVEF greater than 40% No poorly controlled arrhythmias No prior coronary&#xD;
        artery disease No congestive heart failure within last year No myocardial infarction within&#xD;
        past 2 years Other: No active infection No grade 3 regimen related toxicity according to&#xD;
        Bearman model No allergy to paclitaxel, trastuzumab, or benzyl alcohol No grade 3&#xD;
        peripheral neuropathy with last chemotherapy HIV negative Not pregnant or nursing Fertile&#xD;
        patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Chemotherapy: See&#xD;
        Disease Characteristics Endocrine therapy: Concurrent antihormonal therapy (tamoxifen or&#xD;
        anastrozole) allowed as clinically indicated for hormone receptor positive disease&#xD;
        Radiotherapy: Not specified Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leona A. Holmberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2004</study_first_posted>
  <last_update_submitted>March 31, 2010</last_update_submitted>
  <last_update_submitted_qc>March 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 2, 2010</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

